POC(Point of Care) 분자진단 시장 : 용도별, 기술별, 시행 장소별, 제품별 및 국가별 - 경영진 및 분석 첨부(2026-2030년)

Report Overview:

Can a rapidly growing market expand even faster? Find out all about it in this comprehensive report on Molecular Diagnostics at the Point of Care.

Point-of-Care (POC) Molecular Diagnostics represent one of the fastest growing segments of the in vitro diagnostics (IVD) industry, combining the analytical sensitivity of nucleic acid-based testing with the speed and convenience of decentralized healthcare delivery. Molecular diagnostic technologies detect DNA or RNA associated with pathogens or genetic biomarkers, enabling highly accurate detection of disease at early stages. POC molecular systems are designed to deliver results rapidly at or near the site of patient care, reducing dependence on centralized laboratories and supporting timely clinical decision-making.

The global POC molecular diagnostics market is estimated to be approximately USD 4.9 billion in 2025 and is projected to grow at compound annual growth rates of 7.8% reaching 7.2 billion in 2030. Growth is driven by increasing demand for rapid infectious disease diagnosis, expansion of decentralized healthcare models, advances in miniaturized molecular testing technologies, and increasing emphasis on improving clinical workflow efficiency.

POC molecular diagnostics are particularly valuable in clinical environments where rapid diagnosis can influence immediate treatment decisions, including emergency departments, urgent care centers, physician offices, pharmacies, and outpatient clinics. Rapid testing enables earlier initiation of appropriate therapies and may reduce unnecessary use of broad-spectrum antibiotics.

The COVID-19 pandemic increased awareness of the importance of rapid molecular diagnostic testing and accelerated development of portable molecular testing platforms. The installed base of decentralized molecular diagnostic instruments is expected to support continued growth in non-COVID infectious disease testing applications.

Technology Overview

POC molecular diagnostic systems use nucleic acid amplification technologies adapted for simplified workflows and decentralized environments. Polymerase chain reaction (PCR) remains one of the most widely used technologies due to high sensitivity and specificity. Real-time PCR enables rapid detection and quantification of pathogen genetic material in clinical samples.

Isothermal amplification technologies such as loop-mediated isothermal amplification (LAMP), helicase-dependent amplification (HDA), and recombinase polymerase amplification (RPA) enable molecular testing without complex thermal cycling equipment. These technologies support development of portable testing devices with simplified instrument requirements.

Microfluidics technologies enable miniaturization of laboratory processes into cartridge-based systems that integrate sample preparation, amplification, and detection steps.

Fully integrated molecular diagnostic cartridges reduce need for manual sample processing and minimize contamination risk.

Advances in assay chemistry are improving analytical sensitivity and reducing time to result.

Connectivity features enable transmission of test results to laboratory information systems or electronic health records.

Integration with digital health platforms may support clinical decision-making and epidemiological monitoring.

Key Applications

Infectious disease testing represents the largest application segment for POC molecular diagnostics. Respiratory infection testing is widely used to detect pathogens such as influenza virus, respiratory syncytial virus (RSV), SARS-CoV-2, and other respiratory organisms.

Sexually transmitted infection (STI) testing represents another important application area, including detection of pathogens such as Chlamydia trachomatis and Neisseria gonorrhoeae.

Gastrointestinal infection testing enables detection of pathogens associated with diarrheal disease.

Healthcare-associated infection testing supports infection control efforts in hospitals and outpatient care settings.

POC molecular diagnostics may also be used for detection of antimicrobial resistance markers.

Emerging applications include genetic testing and oncology biomarker detection in decentralized settings.

Rapid diagnostic results may support improved patient triage and treatment selection.

POC molecular testing may reduce need for follow-up visits and improve patient convenience.

Market Drivers

Several factors are driving growth in the POC molecular diagnostics market.

Increasing demand for rapid diagnostic results is supporting adoption of decentralized testing solutions.

Healthcare systems are seeking technologies that improve workflow efficiency and reduce patient wait times.

Growing awareness of antimicrobial resistance is increasing demand for accurate pathogen identification.

Advances in molecular biology technologies are enabling development of compact diagnostic devices.

Expansion of outpatient care settings is increasing need for near-patient diagnostic capabilities.

Integration of diagnostics with digital health platforms is improving connectivity and data management.

Healthcare providers are seeking tools that support timely clinical decision-making.

Increased investment in infectious disease preparedness is supporting adoption of rapid molecular testing technologies.

Decentralization of healthcare delivery is supporting expansion of point-of-care testing.

Market Segmentation

The POC molecular diagnostics market can be segmented by technology, application, end user, and geographic region.

By technology, PCR-based systems represent a significant portion of the market, followed by isothermal amplification technologies and emerging molecular detection methods.

By application, infectious disease testing represents the largest segment, particularly respiratory infection testing. Additional segments include sexually transmitted infections, gastrointestinal infections, and hospital-acquired infections.

End users include hospitals, physician offices, urgent care clinics, pharmacies, and other healthcare environments.

North America represents a major regional market due to advanced healthcare infrastructure and high adoption of diagnostic technologies.

Europe represents a significant market supported by healthcare innovation initiatives.

Asia-Pacific markets are expanding due to increasing investment in healthcare infrastructure and diagnostic technologies.

Emerging markets may benefit from portable diagnostic technologies due to limited access to centralized laboratories.

Competitive Landscape

The POC molecular diagnostics market includes multinational diagnostic companies, specialized molecular diagnostics developers, and emerging biotechnology firms.

Competition is influenced by test sensitivity, specificity, ease of use, turnaround time, and breadth of test menu.

Instrument placement strategies often involve long-term consumable supply agreements.

Recurring revenue from test cartridges represents an important component of business models.

Companies are increasingly developing integrated diagnostic platforms combining instrumentation, consumables, and software.

Digital connectivity features are becoming important differentiators.

Strategic partnerships between diagnostic companies and healthcare providers support product adoption.

Innovation in cartridge design and assay chemistry influences competitive positioning.

Future Outlook

The POC molecular diagnostics market is expected to continue expanding as healthcare systems emphasize rapid diagnosis and decentralized care delivery.

Multiplex molecular testing panels may expand diagnostic capabilities within decentralized environments.

Advances in microfluidics and biosensor technologies may further miniaturize molecular diagnostic platforms.

Artificial intelligence tools may improve interpretation of molecular diagnostic data.

Integration with telehealth platforms may support remote patient management.

Expansion of infectious disease surveillance programs may increase adoption of rapid molecular testing.

Overall, point-of-care molecular diagnostics represent an important component of modern healthcare delivery, providing rapid and accurate diagnostic information at the time of patient care. Continued advances in molecular biology technologies and digital health integration are expected to support sustained market growth.

Table of Contents

1 Market Guides

• 1.1 Strategic Situation Analysis
  • 1.1.1 Strategic Role in Rapid Clinical Decision-Making
  • 1.1.2 Technology Platforms and Innovation
  • 1.1.3 Cost Structure and Economic Considerations
  • 1.1.4 Test Menu Expansion and Clinical Utility
  • 1.1.5 Regulatory and Quality Requirements
  • 1.1.6 Competition from Centralized Laboratory Testing
  • 1.1.7 Workflow Integration and Ease of Use
  • 1.1.8 Competitive Landscape and Industry Structure
  • 1.1.9 Geographic Market Dynamics
  • 1.1.10 Outlook and Strategic Implications
• 1.2 Guide for Executives, Marketing and Business Development Staff
• 1.3 Guide for Management Consultants and Investment Advisors
• 1.4 Impact of Artificial Intelligence

2 Introduction and Market Definition

• 2.1 What are Molecular Diagnostics at the Point of Care?
• 2.2 The Diagnostics Revolution
• 2.3 Market Definition
  • 2.3.1 Revenues
• 2.4 Methodology
  • 2.4.1 Methodology
  • 2.4.2 Sources
  • 2.4.3 Authors
• 2.5 Perspective: Healthcare Spending
  • 2.5.1 Global Healthcare Spending
  • 2.5.2 Spending on Healthcare and Pharmaceuticals
  • 2.5.3 Spending on Diagnostics
  • 2.5.4 Important Role of Insurance for Medical Services

3 Instrumentation, Automation and Diagnostic Trends

• 3.1 Instrumentation and Automation
  • 3.1.1 Traditional Automation and Centralization
  • 3.1.2 The New Automation, Decentralization and Point Of Care
  • 3.1.3 Instruments Key to Market Share
  • 3.1.4 Bioinformatics Plays a Role
  • 3.1.5 PCR Takes Command
  • 3.1.6 Next Generation Sequencing Fuels a Revolution
  • 3.1.7 NGS Impact on Pricing
  • 3.1.8 Whole Genome Sequencing, A Brave New World
  • 3.1.9 Companion Diagnostics Blurs Diagnosis and Treatment

4 Industry Overview

• 4.1 Players in a Dynamic Market
  • 4.1.1 Academic Research Lab
  • 4.1.2 Diagnostic Test Developer
  • 4.1.3 Instrumentation Supplier
  • 4.1.4 Chemical/Reagent Supplier
  • 4.1.5 Pathology Supplier
  • 4.1.6 Independent Clinical Laboratory
  • 4.1.7 Public National/regional Laboratory
  • 4.1.8 Hospital Laboratory
  • 4.1.9 Physicians Office Lab (POLS)
  • 4.1.10 Audit Body
  • 4.1.11 Certification Body
• 4.2 The Clinical Laboratory Market Segments
  • 4.2.1 Traditional Market Segmentation
  • 4.2.2 Laboratory Focus and Segmentation
• 4.3 Industry Structure
  • 4.3.1 Hospital Testing Share
  • 4.3.2 Economies of Scale
    • 4.3.2.1 Hospital vs. Central Lab
  • 4.3.3 Physician Office Lab's
  • 4.3.4 Physician's and POCT

5 Profiles of Key MDx Companies

• 5.1 Abbott Laboratories
• 5.2 Abionic
• 5.3 Accelerate Diagnostics
• 5.4 Access Bio
• 5.5 Ador Diagnostics
• 5.6 ADT Biotech
• 5.7 Akonni Biosystems
• 5.8 Alveo Technologies
• 5.9 Anitoa
• 5.10 Applied BioCode
• 5.11 Aureum Diagnostics
• 5.12 Aus Diagnostics
• 5.13 Autonomous Medical Devices
• 5.14 Baebies
• 5.15 Beckman Coulter Diagnostics (Danaher)
• 5.16 Becton, Dickinson and Company
• 5.17 Binx Health
• 5.18 Biocartis
• 5.19 BioFire Diagnostics (bioMerieux)
• 5.20 bioMerieux Diagnostics
• 5.21 Bio-Rad Laboratories, Inc
• 5.22 Bosch Healthcare Solutions GmbH
• 5.23 Cepheid (Danaher)
• 5.24 Credo Diagnostics Biomedical
• 5.25 Cue Health
• 5.26 Curetis (OpGen)
• 5.27 Detect
• 5.28 Diagenode Diagnostics (Hologic)
• 5.29 Diasorin S.p.A.
• 5.30 DNAe
• 5.31 Domus Diagnostics
• 5.32 Enzo Biochem
• 5.33 Eurofins Scientific
• 5.34 Fluxergy
• 5.35 Fusion Genomics.
• 5.36 Genedrive
• 5.37 Genetic Signatures
• 5.38 GenMark Dx (Roche)
• 5.39 Genomadix
• 5.40 Getlabs
• 5.41 Global Access Diagnostics
• 5.42 Grip Molecular Technologies
• 5.43 Hologic
• 5.44 Immunexpress
• 5.45 Inflammatix
• 5.46 Invetech
• 5.47 Iollo
• 5.48 J&J Innovative Medicine
• 5.49 Karius
• 5.50 Lucira Health (Pfizer)
• 5.51 LumiraDx
• 5.52 Maxim Biomedical
• 5.53 Meep
• 5.54 Meridian Bioscience
• 5.55 Millipore Sigma
• 5.56 Molbio Diagnostics
• 5.57 NanoDx
• 5.58 Nanomix
• 5.59 Novacyt
• 5.60 Novel Microdevices
• 5.61 Novus Diagnostics
• 5.62 Nuclein
• 5.63 OnsiteGene
• 5.64 Operon
• 5.65 OraSure Technologies
• 5.66 Oxford Nanopore Technologies
• 5.67 Panagene
• 5.68 Prenetics
• 5.69 Primerdesign (Novacyt)
• 5.70 Prominex
• 5.71 Proof Diagnostics
• 5.72 Qiagen
• 5.73 QuantuMDx
• 5.74 QuidelOrtho
• 5.75 R-Biopharm AG
• 5.76 Response Biomedical
• 5.77 Revvity
• 5.78 Roche Diagnostics
• 5.79 Salignostics
• 5.80 SD Biosensor
• 5.81 Seegene
• 5.82 Sekisui Diagnostics
• 5.83 Siemens Healthineers
• 5.84 Sona Nanotech
• 5.85 SpeeDx
• 5.86 T2 Biosystems
• 5.87 Talis Biomedical
• 5.88 Thermo Fisher Scientific
• 5.89 Uniogen
• 5.90 Veramarx
• 5.91 Veredus Laboratories
• 5.92 XCR Diagnostics
• 5.93 Zhejiang Orient Gene Biotech

6 Market Trends

• 6.1 Factors Driving Growth
  • 6.1.1 New Genotypes Creating New Markets
  • 6.1.2 Aging Population a Boon for All Diagnostics
  • 6.1.3 Developing World Driving ID Dx Growth
  • 6.1.4 Point of Care - Why Centralization is Losing Steam
  • 6.1.5 Self Testing
  • 6.1.6 The Need for Speed
• 6.2 Factors Limiting Growth
  • 6.2.1 Lower Costs
  • 6.2.2 Infectious Disease is Declining
  • 6.2.3 Wellness Hurts
  • 6.2.4 Economic Growth improves Living Standards

7 Molecular Dx - Infectious Disease Recent Developments

• 7.1 Recent Developments - Importance and How to Use This Section
  • 7.1.1 Importance of These Developments
  • 7.1.2 How to Use This Section
• 7.2 Cubit Dx Secures Funding for High-Sensitivity, Low-Cost Platform
• 7.3 Roche receives FDA clearance for STI at POC
• 7.4 Smartphone-Enabled Platform Transforms POC Testing
• 7.5 Credo Preps MDx System, Multiplex Respiratory Test for US Launch
• 7.6 A low-cost CRISPR-based paper strip test for flu
• 7.7 AMDI Receives Award to Develop 10 Minute POC Respiratory Panel
• 7.8 Roche to Acquire LumiraDx Point-of-Care Testing Tech
• 7.9 DiaSorin to Deliver Updated Instruments, New Assays in 2024/25
• 7.10 ReadyGo Diagnostics, Gemina Labs Expand MDx Pact
• 7.11 DiagMetrics Developing Breath Assays
• 7.12 Fortis Life Sciences Acquires IPOC
• 7.13 Domus Diagnostics Wins NIH RADx Tech Contract
• 7.14 Llusern Scientific to Launch POC MDx UTI Panel
• 7.15 Altratech Enters POC MDx Testing Space with Unique Tech
• 7.16 BioMerieux SpotFire MDx POC System Leverages Novel Approach
• 7.17 Katalyst Labs to Distribute ProtonDx Dragonfly Rapid IVD System
• 7.18 LEX Diagnostics Developing Ultra-Fast Low-Cost PCR
• 7.19 Sherlock Biosciences Adds to Infectious Disease Dx Toolkit
• 7.20 NanoDx Prepares for Point-of-Care Commercialization
• 7.21 Paragraf to Study New POC Test to Guide Antibiotic Selection
• 7.22 MicroGEM to Expand 30-Minute RT-PCR System
• 7.23 Startup Detect to Roll Out Next-Gen Molecular Instrument
• 7.24 Diagnostics for the Real World Third-Generation POC Platform
• 7.25 Salignostics Closes Funding Round
• 7.26 Cue Health Targets DTC Market in 2022
• 7.27 Grip Molecular Developing Home Respiratory Panel
• 7.28 Mainz Biomed Developing Home ColoAlert Assay
• 7.29 MFB Fertility Closes Series A Financing Round
• 7.30 Home Test Company Prenetics to go Public
• 7.31 Roche to Acquire TIB Molbiol to Expand Infectious Disease Portfolio
• 7.32 BforCure Preparing Multiple Panels for Point-of-Care qPCR Platform
• 7.33 Talis Biomedical Discusses Point-of-Care
• 7.34 Roche to Acquire GenMark Diagnostics for $1.8B
• 7.35 Pandemic Pushes Handheld qPCR Devices Closer to Commercialization
• 7.36 Hologic to Acquire Mobidiag
• 7.37 Lucira Health Focuses on User Friendly Approach to Home Testing
• 7.38 Infectious Disease Dx Firm Talis Biomedical Raises $254M in IPO
• 7.39 Fluidigm Plans 'Durable' Diagnostics, Clinical Business
• 7.40 Thermo Fisher Scientific to Acquire Mesa Biotech for Up to $550M
• 7.41 Mammoth Biosciences Developing Pathogen Detection Tech
• 7.42 Illumina, IDbyDNA Developing Sequencing-Based Respiratory Tests
• 7.43 Scanogen Developing 90 Minute Infection Test
• 7.44 Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
• 7.45 FDA Provides Self Testing SARS-CoV-2 EAU Guidance
• 7.46 Mammoth Biosciences Announces Rapid, CRISPR-Based COVID-19 Diagnostic
• 7.47 Genetic Signatures Gets CE Mark for Coronavirus Molecular Test
• 7.48 Qiagen Respiratory Panel with Coronavirus Receives CE Mark
• 7.49 Lumos Diagnostics Closes $15M Series A Funding

8 The Global Market for Molecular Diagnostics at the Point of Care

• 8.1 Global Market Overview by Country
  • 8.1.1 Table - Global Market by Country
  • 8.1.2 Chart - Global Market by Country
• 8.2 Global Market by Application - Overview
  • 8.2.1 Table - Global Market by Application
  • 8.2.2 Chart - Global Market by Application - Base/Final Year Comparison
  • 8.2.3 Chart - Global Market by Application - Base Year
  • 8.2.4 Chart - Global Market by Application - End Year
  • 8.2.5 Chart - Global Market by Application - Share by Year
  • 8.2.6 Chart - Global Market by Application - Segments Growth
• 8.3 Global Market by Technology - Overview
  • 8.3.1 Table - Global Market by Technology
  • 8.3.2 Chart - Global Market by Technology - Base/Final Year Comparison
  • 8.3.3 Chart - Global Market by Technology - Base Year
  • 8.3.4 Chart - Global Market by Technology - End Year
  • 8.3.5 Chart - Global Market by Technology - Share by Year
  • 8.3.6 Chart - Global Market by Technology - Segments Growth
• 8.4 Global Market by Place - Overview
  • 8.4.1 Table - Global Market by Place
  • 8.4.2 Chart - Global Market by Place - Base/Final Year Comparison
  • 8.4.3 Chart - Global Market by Place - Base Year
  • 8.4.4 Chart - Global Market by Place - End Year
  • 8.4.5 Chart - Global Market by Place - Share by Year
  • 8.4.6 Chart - Global Market by Place - Segments Growth
• 8.5 Global Market by Product - Overview
  • 8.5.1 Table - Global Market by Product
  • 8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
  • 8.5.3 Chart - Global Market by Product - Base Year
  • 8.5.4 Chart - Global Market by Product - End Year
  • 8.5.5 Chart - Global Market by Product - Share by Year
  • 8.5.6 Chart - Global Market by Product - Segments Growth

9 Global MDx at the Point of Care Markets - By Application

• 9.1 Respiratory Infectious Disease
  • 9.1.1 Table Respiratory Infectious Disease - by Country
  • 9.1.2 Chart - Respiratory Infectious Disease Growth
• 9.2 Gastrointestinal Infectious Disease
  • 9.2.1 Table Gastrointestinal Infectious Disease - by Country
  • 9.2.2 Chart - Gastrointestinal Infectious Disease Growth
• 9.3 Sexually Transmitted Disease
  • 9.3.1 Table Sexually Transmitted Disease - by Country
  • 9.3.2 Chart - Sexually Transmitted Disease Growth
• 9.4 Other Application
  • 9.4.1 Table Other Application - by Country
  • 9.4.2 Chart - Other Application Growth

10 Global MDx Markets at the Point of Care - by Technology

• 10.1 PCR
  • 10.1.1 Table PCR - by Country
  • 10.1.2 Chart - PCR Growth
• 10.2 NGS/Probe
  • 10.2.1 Table NGS/Probe - by Country
  • 10.2.2 Chart - NGS/Probe Growth
• 10.3 Other Technology
  • 10.3.1 Table Other Technology - by Country
  • 10.3.2 Chart - Other Technology Growth

11 Global MDx at the Point of Care Markets - by Place

• 11.1 Hospital Point of Care
  • 11.1.1 Table Hospital Point of Care - by Country
  • 11.1.2 Chart - Hospital Point of Care Growth
• 11.2 Clinic or Physician Office Lab
  • 11.2.1 Table Clinic or Physician Office Lab - by Country
  • 11.2.2 Chart - Clinic or Physician Office Lab Growth
• 11.3 Seniors Facility
  • 11.3.1 Table Seniors Facility - by Country
  • 11.3.2 Chart - Seniors Facility Growth
• 11.4 Other Place
  • 11.4.1 Table Other Place? by Country
  • 11.4.2 Chart - Other Place Growth

12 Global MDx at the Point of Care Markets - by Product

• 12.1 Instrument
  • 12.1.1 Table Instrument - by Country
  • 12.1.2 Chart - Instrument Growth
• 12.2 Cartridge
  • 12.2.1 Table Cartridge - by Country
  • 12.2.2 Chart - Cartridge Growth
• 12.3 Other Product
  • 12.3.1 Table Other Product - by Country
  • 12.3.2 Chart - Other Product Growth

13 Appendices

• 13.1 Growth of Approved IVD Test Menu
• 13.2 Growth of Approved Average IVD Test Fee
• 13.3 The Most Used IVD Assays
• 13.4 The Highest Grossing Assays
• 13.5 Laboratory Fees Schedule

Table of Tables

• Table 1 Seven Key Diagnostic Laboratory Technology Trends
• Table 2 Market Players by Type
• Table 3 Clinical Laboratory Departments and Segments
• Table 4 Laboratory Management Focus - Different Approaches
• Table 5 Key Segmentation Variables Going Forward
• Table 6 Five Factors Driving Growth
• Table 7 Four Factors Limiting Growth
• Table 8 - Global Market by Region
• Table 9 Global Market by Application
• Table 10 Global Market by Technology
• Table 11 Global Market by Place
• Table 12 Global Market by Product
• Table 13 Respiratory Infectious Disease by Country
• Table 14 Gastrointestinal Infectious Disease by Country
• Table 15 Sexually Transmitted Disease by Country
• Table 16 Other Application by Country
• Table 17 PCR by Country
• Table 18 NGS/Probe by Country
• Table 19 Other Technology by Country
• Table 20 Hospital Point of Care by Country
• Table 21 Clinic or Physician Office Lab by Country
• Table 22 Seniors Facility by Country
• Table 23 Other Place by Country
• Table 24 Instrument by Country
• Table 25 Cartridge by Country
• Table 26 Other Product by Country
• Table 27 The Most Common Assays
• Table 28 Largest Revenue Assays
• Table 29 Clinical Lab Fee Schedule

Table of Figures

• Figure 1 Global Healthcare Spending
• Figure 2 Centralized vs. Decentralized Laboratory Service
• Figure 3 A Highly Multiplexed Syndromic Testing Unit
• Figure 4 The Real Cost to Sequence the Human Genome
• Figure 5 The Codevelopment Process
• Figure 6 The Road to Diagnostics
• Figure 7 Percentage of World Population Over 65
• Figure 8 Chart Infectious Disease Decline
• Figure 9 Global Market Shares Chart
• Figure 10 Global Market by Application - Base vs. Final
• Figure 11 Global Market by Application Base Year
• Figure 12 Global Market by Application End Year
• Figure 13 Application Share by Year
• Figure 14 Application Segments Growth
• Figure 15 Global Market by Technology - Base vs. Final
• Figure 16 Global Market by Technology Base Year
• Figure 17 Global Market by Technology End Year
• Figure 18 Technology Share by Year
• Figure 19 Technology Segments Growth
• Figure 20 Global Market by Place - Base vs. Final
• Figure 21 Global Market by Place Base Year
• Figure 22 Global Market by Place End Year
• Figure 23 Place Share by Year
• Figure 24 Place Segments Growth
• Figure 25 Global Market by Product - Base vs. Final
• Figure 26 Global Market by Product Base Year
• Figure 27 Global Market by Product End Year
• Figure 28 Product Share by Year
• Figure 29 Product Segments Growth
• Figure 30 Respiratory Infectious Disease Diagnostics Growth
• Figure 31 Gastrointestinal Infectious Disease Growth
• Figure 32 Sexually Transmitted Disease Growth
• Figure 33 Other Application Growth
• Figure 34 PCR Growth
• Figure 35 NGS/Probe Growth
• Figure 36 Other Technology Growth
• Figure 37 Hospital Point of Care Growth
• Figure 38 Clinic or Physician Office Lab Growth
• Figure 39 Seniors Facility Growth
• Figure 40 Other Place Growth
• Figure 41 Instrument Growth
• Figure 42 Cartridge Growth
• Figure 43 Other Product Growth
• Figure 44 IVD Test Menu Growth
• Figure 45 IVD Test Average Fees - A Ten Year View